Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab
Open Access
- 29 September 2005
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 19 (11) , 2005-2008
- https://doi.org/10.1038/sj.leu.2403956
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Perspectives in the treatment of LGL leukemiaLeukemia Research, 2005
- Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatmentLeukemia Research, 2005
- Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemiaLeukemia, 2004
- Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemiaLeukemia, 2004
- Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)British Journal of Haematology, 2003
- Association of pure red cell aplasia with T large granular lymphocyte leukaemiaJournal of Clinical Pathology, 1998
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997